SCHEDULE: Morgan Stanley Reduces Chemomab Stake Below 5%

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have reported ceasing to be beneficial owners of more than five percent of Chemomab Therapeutics Ltd.'s ordinary shares.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, filed an Amendment No. 1 to Schedule 13G for Chemomab Therapeutics Ltd.
• As of July 31, 2025, Morgan Stanley's aggregate beneficial ownership of Chemomab Therapeutics Ltd. ordinary shares/American Depositary Shares is 13,213,260 shares, representing 3.2% of the class.
• Morgan Stanley & Co. LLC's aggregate beneficial ownership is 9,275,360 shares, representing 2.2% of the class.
• Both entities have ceased to be beneficial owners of more than five percent of the class of securities.
• The filing indicates shared voting and dispositive power for the reported shares by both Morgan Stanley and Morgan Stanley & Co. LLC.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of a change in beneficial ownership, not a performance report. The reduction in stake could be interpreted negatively by some, but it's a standard portfolio adjustment.

Negatives

• The reduction in beneficial ownership below the 5% threshold by a major institutional investor like Morgan Stanley could be perceived negatively by the market, potentially signaling a decrease in institutional confidence or a reallocation of capital.

Future Outlook

NA

Industry Context

Schedule 13G filings are routine disclosures by passive institutional investors who acquire or cease to hold more than 5% of a company's outstanding shares. This filing indicates a reduction in Morgan Stanley's stake in Chemomab Therapeutics Ltd. below the 5% threshold, which is a common occurrence as investment firms adjust their portfolios.

Stakeholder Impact

• Primarily impacts shareholders and potential investors who monitor institutional ownership trends. A reduction in a significant institutional stake might influence investor sentiment and trading decisions.

Key Dates

Keywords

Chemomab Therapeutics, Morgan Stanley, Schedule 13G, Beneficial Ownership, Institutional Investor, Shareholding, SEC Filing, CMOM, American Depositary Shares, Ordinary Shares